| 11851680 |
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) |
Aaron Martin, Michelle Brenda Pires |
2023-12-26 |
$851,000 |
| 11453861 |
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) |
Aaron Martin, Michelle Brenda Pires |
2022-09-27 |
$2,830,000 |
| 11384335 |
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) |
Aaron Martin |
2022-07-12 |
$3,305,000 |
| 11186822 |
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) |
Aaron Martin |
2021-11-30 |
$9,753,000 |
| 11008548 |
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) |
Aaron Martin, Michelle Brenda Pires |
2021-05-18 |
$11,409,000 |
| 10138483 |
Transferrin/transferrin receptor-mediated siRNA delivery |
Abbot F. Clark |
2018-11-27 |
$25,009,000 |
| 9932584 |
Interfering RNA delivery system and uses thereof |
Ying Yu |
2018-04-03 |
$5,596,000 |
| 9795684 |
Interfering RNA delivery system and uses thereof |
— |
2017-10-24 |
|
| 9765340 |
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders |
John M. Yanni, Daniel A. Gamache, Steven T. Miller |
2017-09-19 |
$6,611,000 |
| 9752147 |
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions |
Abbot F. Clark, Martin B. Wax |
2017-09-05 |
$2,890,000 |
| 9745585 |
RNAi-mediated inhibition of histamine receptor H1-related conditions |
John M. Yanni, Daniel A. Gamache, Steven T. Miller |
2017-08-29 |
$5,110,000 |
| 9562230 |
Transferrin/transferrin receptor-mediated siRNA delivery |
Abbot F. Clark |
2017-02-07 |
$3,477,000 |
| 9550994 |
RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
Abbot F. Clark, Wan-Heng Wang, Loretta McNatt |
2017-01-24 |
$3,052,000 |
| 9526799 |
Low density lipoprotein receptor-mediated siRNA delivery |
— |
2016-12-27 |
$1,385,000 |
| 9476047 |
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions |
Abbot F. Clark, Martin B. Wax |
2016-10-25 |
$1,990,000 |
| 9447419 |
RNAi-mediated inhibition of tumor necrosis factor α-related conditions |
John M. Yanni, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller |
2016-09-20 |
$7,077,000 |
| 9422556 |
RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis |
Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers |
2016-08-23 |
$7,136,000 |
| 9371529 |
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
John M. Yanni, Daniel A. Gamache, Steven T. Miller |
2016-06-21 |
$5,026,000 |
| 9347062 |
Interfering RNA delivery system and uses thereof |
Ying Yu |
2016-05-24 |
$4,974,000 |
| 9289514 |
Low density lipoprotein receptor-mediated siRNA delivery |
— |
2016-03-22 |
$3,858,000 |
| 9233170 |
Interfering RNA delivery system and uses thereof |
— |
2016-01-12 |
$4,107,000 |
| 9206428 |
RNAi-mediated inhibition of histamine receptor H1-related conditions |
John M. Yanni, Daniel A. Gamache, Steven T. Miller |
2015-12-08 |
$5,606,000 |
| 9173896 |
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions |
Abbot F. Clark, Martin B. Wax |
2015-11-03 |
$5,045,000 |
| 9150862 |
siRNA targeting VEGFA and methods for treatment in vivo |
Anja Smith, Angela Reynolds, Xinyu Zhang |
2015-10-06 |
$150,252,000 |
| 9139834 |
RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis |
Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers |
2015-09-22 |
$4,220,000 |
